Advanced search
Start date
Betweenand

Melanoma and chemoresistance: in vitro and in silico models to exploit therapeutic targets

Abstract

Melanoma is a highly invasive and metastatic cancer, with high rates of mortality and chemoresistance. The MAPK pathway is constitutively activated, and there are already available powerful target-specific chemotherapeutics, such as BRAF inhibitors (vemurafenib and dabrafenib). However, resistance to BRAF inhibitors is observed after about 7 months of treatment, primarily because of the high degree of phenotypic, genetic and epigenetic intra-tumor heterogeneity. Although, combination therapies benefit patients, and immunotherapy has shown highly promising results, overcoming resistance remains major challenge. In silico screening studies from our laboratory using the TCGA and Gene Expression Omnibus (GEO) databases identified a collection of genes as being differentially expressed between invasive melanoma when compared with nevi (non-malignant lesion). Understanding the role and regulation of specifics genes should provide insights into the molecular mechanisms underpinning melanoma progression and ultimately resistance to therapy. In this study we will characterize the action of TOP1, ATP6V0B, ADK, PEMT and SINB3 genes in humans and vemurafenib-resistant Melanomas. This thematic project aim to complex process of the microenvironment, aging and metabolic process, and IDO and imune response. The objective is to identify target genes and mechanisms that contribute to vemurafenib resistance. To achieve this goal, the gene expression will be explored in a broad panel of human Melanomas at different stages of progression and mutation status, as well as in vemurafenib-sensitive and resistant cell lines. We will employ both monolayer culture and organotypic models that simulate invasion in reconstructed skin containing Melanoma, and explore histological samples from patients coming from a partnership with the Barretos Cancer Hospital. We will dissect the molecular pathways associated with these gene expression, as well as IDO, using gene manipulating tools (shRNA/CRISPR CAS9), and evaluate the impact of them on proliferation, migration, invasion, angiogenesis, and cell death induction. This study, like others already developed in our laboratory, can characterize genes that generate tumor subpopulations of resistant cells and aims at identifying pharmacologically tractable targets that may be used in combination to enhance therapeutic response. (AU)

Scientific publications (9)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
MINI, C. A.; DREOSSI, S. A. C.; ABE, F. R.; MARIA-ENGLER, S. S.; OLIVEIRA, D. P. Immortalized keratinocytes cells generates an effective model of Epidermal Human Equivalent for irritation and corrosion tests. TOXICOLOGY IN VITRO, v. 71, MAR 2021. Web of Science Citations: 0.
HIEDA, DANIELE SEO; DA COSTA CARVALHO, LARISSA ANASTACIO; DE MELLO, BARBARA VAZ; DE OLIVEIRA, ERICA APARECIDA; DE ASSIS, SILVIA ROMANO; WU, JOANNA; DU-THUMM, LAURENCE; VIANA DA SILVA, CLAUDIA LARISSA; ROUBICEK, DEBORAH ARNSDORFF; MARIA-ENGLER, SILVYA STUCHI; DE MORAES BARROS, SILVIA BERLANGA. Air Particulate Matter Induces Skin Barrier Dysfunction and Water Transport Alteration on a Reconstructed Human Epidermis Model. JOURNAL OF INVESTIGATIVE DERMATOLOGY, v. 140, n. 12, p. 2343+, DEC 2020. Web of Science Citations: 1.
MALLAUPOMA CAMARENA, DENISSE ESTHER; ALCANTARA SEKIMOTO MATSUYAMA, LARISSA SATIKO; MARIA-ENGLER, SILVYA STUCHI; CATALANI, LUIZ HENRIQUE. Development of Epidermal Equivalent from Electrospun Synthetic Polymers for In Vitro Irritation/Corrosion Testing. NANOMATERIALS, v. 10, n. 12 DEC 2020. Web of Science Citations: 0.
SANDRI, SILVANA; WATANABE, LUIS R. M.; DE OLIVEIRA, ERICA APARECIDA; FAIAO-FLORES, FERNANDA; MIGLIORINI, SILENE; TIAGO, MANOELA; FELIPE-SILVA, ALOISIO; VAZQUEZ, VINICIUS DE LIMA; SOUZA, PAOLA DA COSTA; LOPES CONSOLARO, MARCIA EDILAINE; CAMPA, ANA; MARIA-ENGLER, SILVYA STUCHI. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. PHARMACOLOGICAL RESEARCH, v. 159, SEP 2020. Web of Science Citations: 0.
FERRAZ, LETICIA SILVA; DA COSTA, RENATA TORRES; DA COSTA, CLAUDIA ALVES; JOAO RIBEIRO, CESAR AUGUSTO; ARRUDA, DENISE COSTA; MARIA-ENGLER, SILVYA STUCHI; RODRIGUES, TIAGO. Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics. Biochemical Pharmacology, v. 178, AUG 2020. Web of Science Citations: 0.
ALVES-FERNANDES, DEBORA KRISTINA; DE OLIVEIRA, ERICA APARECIDA; HASTREITER, ARACELI APARECIDA; FAIAO-FLORES, FERNANDA; FELIPE-SILVA, ALOISIO SOUZA; TURATO, WALTER; FOCK, RICARDO AMBROSIO; MARIA-ENGLER, SILVYA STUCHI; DE MORAES BARROS, SILVIA BERLANGA. In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in NRAS-mutant human melanoma. Food and Chemical Toxicology, v. 141, JUL 2020. Web of Science Citations: 0.
DE SOUZA, NAYANE; DE OLIVEIRA, ERICA APARECIDA; FAIAO-FLORES, FERNANDA; PIMENTA, LUCIANA A.; QUINCOCES, JOSE A. P.; SAMPAIO, SANDRA C.; MARIA-ENGLER, SILVYA S. Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v. 20, n. 9, p. 1038-1050, 2020. Web of Science Citations: 0.
VENANCIO, PALOMA ALMEIDA; LOPES CONSOLARO, MARCIA EDILAINE; DERCHAIN, SOPHIE FRANCOISE; BOCCARDO, ENRIQUE; VILLA, LUISA LINA; MARIA-ENGLER, SILVYA STUCHI; CAMPA, ANA; DISCACCIATI, MICHELLE GARCIA. Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer. CANCER CYTOPATHOLOGY, v. 127, n. 9 AUG 2019. Web of Science Citations: 0.
ALVES-FERNANDES, DEBORA KRISTINA; DE OLIVEIR, ERICA APARECIDA; FAIAO-FLORES, FERNANDA; ALICEA-REBECCA, GRETCHEN; WEERARATNA, ASHANI T.; SMALLEY, KEIRAN S. M.; DE MORAES BARROS, SILVIA BERLANGA; MARIA-ENGLER, SILVYA STUCHI. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). PHARMACOLOGICAL RESEARCH, v. 141, p. 63-72, MAR 2019. Web of Science Citations: 1.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.